CRP and COVID-19: A retrospective clinical trial among 22 severe/critical COVID-19 patients indicated that >8 days of treatment with anakinra (IL-1 receptor antagonist) led to a reduced requirement for mechanical ventilation, decreased serum CRP levels, and improved clinical conditions in patients compared to the control group (251).